Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 177,008 shares of the biopharmaceutical company's stock after purchasing an additional 12,757 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.16% of Regeneron Pharmaceuticals worth $127,118,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Amundi grew its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after acquiring an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. Thrivent Financial for Lutherans increased its position in Regeneron Pharmaceuticals by 1,272.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock worth $89,179,000 after purchasing an additional 116,074 shares during the last quarter. Finally, KBC Group NV raised its stake in Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of REGN stock traded down $17.23 during mid-day trading on Tuesday, hitting $617.00. The stock had a trading volume of 1,059,572 shares, compared to its average volume of 677,760. The firm has a market capitalization of $67.45 billion, a P/E ratio of 16.12, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12-month low of $615.00 and a 12-month high of $1,211.20. The firm's 50-day moving average is $681.52 and its two-hundred day moving average is $788.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Bank of America reissued an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.